Heart failure & cardiomyopathies
Distal Ventricular Pacing for Drug-Refractory Mid-Cavity Obstructive Hypertrophic Cardiomyopathy: A Randomized, Placebo-Controlled Trial of Personalized Pacing
Authors' conclusion
In a randomized placebo-controlled trial, PPoP reduces obstruction and improves exercise performance in severely symptomatic patients with LVMCO.
Study context
- Population
- Patients with symptomatic drug-refractory left ventricular (LV) mid-cavity obstructive hypertrophic cardiomyopathy16 met primary end points
- Participants
- 17 patients
- Comparison
- Personalized prescription of pacing vs backup pacing
- Primary endpoint
- Invasive gradient change with best-site pacing
Methodological detailsblinded, placebo-controlled, crossover, 15 entered crossover; 2 withdrawals during crossover
- Blinded
- Placebo-controlled
- Crossover
- 15 entered crossover; 2 withdrawals during crossover
Primary result
LVMCO gradient, baseline vs best-site pacing
Reduction
60%
P < 0.0001
By group
As reported in the abstract
Secondary outcomes
6-minute walk test
P = 0.018
| Outcome | PPoP | Backup pacing |
|---|---|---|
| Preferred setting after crossover | 69% | — not stated in the abstract |
— not stated in the abstract
- Preferred setting after crossover: 13 completed crossover
Other outcome measures
- Other outcome measures also indicated benefit with personalized prescription of pacing (PPoP)
Safety
- Cardiac vein perforation
- 1
Original publication
Distal Ventricular Pacing for Drug-Refractory Mid-Cavity Obstructive Hypertrophic Cardiomyopathy: A Randomized, Placebo-Controlled Trial of Personalized Pacing. Circ Arrhythm Electrophysiol. Published 19 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →